Richard Markus
Analyst
Equibles does not estimate personal net worth.
About Richard Markus
Richard Markus has spoken on 3 earnings calls across 1 company, most recently for Arcus Biosciences, Inc. on May 5, 2026. The companies whose calls Richard Markus spoke on are classified in the Healthcare sector.
Richard Markus on recent calls
“As Terry described, our development plan is designed to establish castatophan as a foundational standard of care in clear cell RCC, so that all patients have the opportunity to benefit from treatment with a castatophan-based regimen across multiple lines of therapy.”
“I'd like to start on slide nine of our corporate deck just to remind everyone about the design of our ARC-20 study. Today's data includes updated ORR and PFS based on a data cutoff date of January 30th from the four late-line monotherapy cohorts highlighted on the slide.”
“I'll first recap the highlights of our recent ASCO-GU presentation for Cas monotherapy in late-line clear-cell renal cell carcinoma. After that, I'll speak about our upcoming data presentations and near-term development plans for Cas.”